Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery
Exalpha Biologicals, Inc.

Glypican-3 (GPC3)

  • Product Code: X2395P
  • Size: 500 µg
  • Price (USD): $249

Cat #

X2395P		 Quantity:      

Data Sheet

Product Name

Glypican-3 (GPC3)


GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7





Product Type

Polyclonal Antibody




IHC (paraffin), WB


Total IgG


500 µg

Price (USD)



Glypican-3 encodes a putative extracellular proteoglycan that is inferred to play an important role in growth control in embryonic mesodermal tissues in which it is selectively expressed. It appears to form a complex with insulin-like growth factor and hence modulate IGF2 action. Glypican-3 is the human homolog of OCI-5, a GPI-linked proteoglycan first isolated from rat intestine. Originally identified as the molecular basis for Simpson-Golabi-Behmel syndrome (SGBS) also called Simpson dysmorphia syndrome (SDYS).


C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)


Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight

65.5 kDa

Product Image

Image Legend

Immunohistochemical staining using GPC3 antibody (Cat. No. X2395P) on human hepatocellular carcinoma tissue. Antibody used at 10 µg/ml. Secondary antibody, HRP conjugated mouse anti-sheep (Cat. No. X1206M), used at 1:20 dilution. Sections heated for 10 minutes with 10 mM sodium citrate.

Database Links:



1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222. 2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230. 3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223. 4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394. 5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224. 6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906. 7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711. 8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990. 9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.